Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 7

1.

A Bayesian adaptive phase 1 design to determine the optimal dose and schedule of an adoptive T-cell therapy in a mixed patient population.

Quintana M, Li DH, Albertson TM, Connor JT.

Contemp Clin Trials. 2016 May;48:153-65. doi: 10.1016/j.cct.2016.04.004. Epub 2016 Apr 19.

PMID:
27109037
2.

DNA replication fidelity and cancer.

Preston BD, Albertson TM, Herr AJ.

Semin Cancer Biol. 2010 Oct;20(5):281-93. doi: 10.1016/j.semcancer.2010.10.009. Epub 2010 Oct 15. Review.

3.

Case series: acute tumor lysis syndrome in mutator mice with disseminated lymphoblastic lymphoma.

Treuting PM, Albertson TM, Preston BD.

Toxicol Pathol. 2010 Apr;38(3):476-85. doi: 10.1177/0192623310362249. Epub 2010 Feb 26.

PMID:
20190201
4.

Divergent cellular phenotypes of human and mouse cells lacking the Werner syndrome RecQ helicase.

Dhillon KK, Sidorova JM, Albertson TM, Anderson JB, Ladiges WC, Rabinovitch PS, Preston BD, Monnat RJ Jr.

DNA Repair (Amst). 2010 Jan 2;9(1):11-22. doi: 10.1016/j.dnarep.2009.09.013. Epub 2009 Nov 5.

5.

DNA polymerase epsilon and delta proofreading suppress discrete mutator and cancer phenotypes in mice.

Albertson TM, Ogawa M, Bugni JM, Hays LE, Chen Y, Wang Y, Treuting PM, Heddle JA, Goldsby RE, Preston BD.

Proc Natl Acad Sci U S A. 2009 Oct 6;106(40):17101-4. doi: 10.1073/pnas.0907147106. Epub 2009 Sep 24.

6.

DNA replication fidelity: proofreading in trans.

Albertson TM, Preston BD.

Curr Biol. 2006 Mar 21;16(6):R209-11.

7.

Supplemental Content

Loading ...
Support Center